ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

ClinicalTrials.gov ID: NCT06525220

Public ClinicalTrials.gov record NCT06525220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 23, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma

Study identification

NCT ID
NCT06525220
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merus B.V.
Industry
Enrollment
700 participants

Conditions and interventions

Interventions

  • Pembrolizumab Drug
  • Petosemtamab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 24, 2024
Primary completion
Dec 31, 2027
Completion
Jun 30, 2030
Last update posted
Apr 21, 2026

2024 – 2030

United States locations

U.S. sites
37
U.S. states
20
U.S. cities
33
Facility City State ZIP Site status
Site 164 Mobile Alabama 36607 Recruiting
Site 36 La Jolla California 92037 Recruiting
Site 27 Los Angeles California 90033 Recruiting
Site 16 Palo Alto California 94304 Recruiting
Site 19 Newark Delaware 19713 Recruiting
Site 108 Washington D.C. District of Columbia 20010 Recruiting
Site 14 Fort Myers Florida 33901 Recruiting
Site 48 Orlando Florida 32804 Withdrawn
Site 8 Orlando Florida 32827 Recruiting
Site 21 St. Petersburg Florida 33705 Recruiting
Site 20 West Palm Beach Florida 33401 Recruiting
Site 171 Atlanta Georgia 30322 Recruiting
Site 197 Chicago Illinois 60611 Recruiting
Site 50 Chicago Illinois 60637 Recruiting
Site 2 Louisville Kentucky 40202 Recruiting
Site 162 Baton Rouge Louisiana 70809 Recruiting
Site 155 Minneapolis Minnesota 55417 Recruiting
Site 168 St Louis Missouri 63108 Recruiting
Site 94 Hackensack New Jersey 07601 Recruiting
Site 6 Albuquerque New Mexico 87131 Recruiting
Site 113 Durham North Carolina 27710 Recruiting
Site 118 Winston-Salem North Carolina 27157 Recruiting
Site 191 Cleveland Ohio 44195 Recruiting
Site 43 Philadelphia Pennsylvania 19104 Recruiting
Site 153 Philadelphia Pennsylvania 19107 Recruiting
Site 154 Philadelphia Pennsylvania 19114 Recruiting
Site 89 Chattanooga Tennessee 37404 Recruiting
Site 115 Memphis Tennessee 38103 Recruiting
Site 88 Nashville Tennessee 37203 Recruiting
Site 22 Austin Texas 78745 Recruiting
Site 1 Houston Texas 77030 Recruiting
Site 18 Plano Texas 75075 Recruiting
Site 17 Sugar Land Texas 77479 Recruiting
Site 15 Tyler Texas 75702 Recruiting
Site 10 Salt Lake City Utah 84112 Recruiting
Site 12 Blacksburg Virginia 24060 Recruiting
Site 23 Norfolk Virginia 23502 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 160 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06525220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2026 · Synced Apr 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06525220 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →